FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321864672> ?p ?o ?g. }

• W2321864672 endingPage "e17" @default.
• W2321864672 startingPage "e15" @default.
• W2321864672 abstract "Interleukin-10 (IL-10) is a key anti-inflammatory cytokine (1,2) and loss-of-function mutations in IL-10 or the IL-10 receptor (IL-10R) have been implicated as a common cause of infantile inflammatory bowel disease (IBD) (3–6). These patients typically present in the first months of life with severe colitis, perianal disease, folliculitis, and, on occasion, arthritis, and are classically refractory to various immunosuppressive agents. Hematopoietic stem cell transplantation (HSCT) has been shown to be curative, but is not available for all of the patients (4–6). The long-term risks of IL-10R deficiency are unclear; however, B-cell lymphomas have recently been reported in untransplanted young children with a known diagnosis of IL-10R deficiency (7). Here we report the discovery of IL-10R deficiency in a patient who presented with severe IBD as an infant and developed a mature B-cell lymphoma in adolescence. Through our interNational Early Onset Pediatric IBD Cohort Study/Care-for-Rare IBD Alliance we were referred a 15-year-old female patient with history of infantile IBD. She developed bloody diarrhea and anal fissures in the first weeks of life, failure to thrive and anemia requiring several blood transfusions by 6 months, and a rectovaginal fistula at 8 months of age. Endoscopic evaluation revealed severe pancolitis, a distal colonic stricture, and pseudopolyps; biopsies demonstrated patchy areas of cryptitis, ulcerations, and lymphocytic infiltration. Her disease was resistant to various medications including steroids and aminosalicylates for the first 5 years, Imuran for the next 3 years, and combination of anti-tumor necrosis factor antibodies and methotrexate for 3 more years. Persistent symptoms led to a partial colectomy and colostomy at 8 months of age and at 5 years of age a subtotal colectomy, Hartmann pouch construction, and permanent ileostomy. Despite these interventions, the patient continued to experience severe perianal fistulizing disease. At 12 years of age the patient presented with 2 months history of right-sided abdominal pain and hepatosplenomegaly. Blood tests demonstrated mild thrombocytopenia, hyperuricemia, and abnormal liver tests (Table 1). An abdominal computed tomography showed hepatosplenomegaly with multiple focal liver lesions accompanied by enlarged mesenteric lymph nodes, all confirmed to be hypermetabolic on positron emission tomography scan (Fig. 1). Liver biopsy revealed CD20-positive, Epstein-Barr virus (EBV)-encoded RNA-negative small round blue cells leading to a diagnosis of mature large B-cell lymphoma. Despite successful initial treatment with cyclophosphamide, vincristine, prednisone, ritixumab, cytarabine, doxorubicin as well as intrathecal methotrexate, cytarabine, and hydrocortisone, remission was maintained for only 2 years. At time of relapse at age 15, salvage chemotherapy of rituximab, ifosfamide, carboplatin, and etoposide was initiated and consolidation with autologous HSCT was being considered at the time of referral.TABLE 1: Laboratory results at presentation with diffuse large B-cell lymphomaFIGURE 1: Imaging and histology results at time of diagnosis with diffuse large B-cell lymphoma. A, Abdominal computed tomography scan showing multiple focal liver lesions (arrow pointing to representative lesion) confirmed to be hypermetabolic on positron emission tomography scan (B). C, Hematoxylin and eosin staining of liver biopsy (×40) showing numerous small round blue tumor cells.We performed IL-10R functional testing on freshly isolated peripheral blood mononuclear cells obtained from the patient and her father who served as a healthy control. Our flow cytometry-based assay measures IL-10–induced phosphorylation of signal transducer and activator of transcription 3 (STAT3), which is a key transcription factor downstream of the IL-10 receptor; IL-6–induced STAT3 phosphorylation serves as an internal positive control. While the patient's IL-6–dependent STAT3 phosphorylation was intact, IL-10–dependent phosphorylation of STAT3 was completely abrogated (Fig. 2A), suggesting abnormalities in the IL-10 receptor or downstream signaling components. Targeted sequencing of IL10R genes revealed novel compound heterozygous mutations in IL10RB (NM_000628.4) comprising a variant on exon 2 (c. 172 A>G; p. S58R) leading to a serine to arginine substitution, predicted by PolyPhen analysis as highly deleterious, and a variant on exon 5 (c. 611 G>A; p. W204X) leading to a stop codon (Fig. 2B). Additional functional assays with monocytes isolated from this patient, as well as other IL-10R–deficient patients, demonstrating an increase in proinflammatory macrophage function and a defect in anti-inflammatory macrophage generation and function have been recently published (2). Because autologous HSCT would be predicted to be ineffective in patients with IL-10R deficiency given the broad requirement of IL-10–dependent signaling in the hematopoietic compartment, the patient was referred for allogeneic HSCT. Four months after matched unrelated allogeneic transplantation, the patient is fully engrafted without any signs of active colitis or lymphoma recurrence, and the rectovaginal fistula is resolving.FIGURE 2: Identification of loss of function mutations in IL10RB. A, Functional analysis of IL-10R was performed by assessing STAT3 phosphorylation using flow cytometry. Peripheral blood mononuclear cells were obtained from the patient and her father who served as a healthy control and cultured without stimuli (unstim.) or with IL-10 20 ng/mL for 30 minutes. Stimulation with IL-6 20 ng/mL served as an internal positive control because it also induces STAT3 phosphorylation. Cells were then fixed, permeabilized, and stained for pSTAT3 (phosphorylated STAT3). B, Targeted sequencing of IL10RB revealed compound heterozygote mutations.DISCUSSION The long-term health risks of IL-10R deficiency in patients with IBD who are not transplanted are unknown. Although HSCT has been shown to be curative, the lack of suitable donors as well as cost, complexity, and potential morbidity and mortality prevent its more widespread use. The patient reported here had a history of severe infantile IBD that was refractory to immunosuppressive medications and surgical interventions, and at 12 years of age-developed B-cell lymphoma. The diagnosis of loss-of-function mutations in the IL10RB gene was confirmed at 15 years of age and altered the treatment plan from autologous to allogeneic HSCT. A recent study by Neven et al (7) showed an association between IL-10R deficiency and B-cell lymphoma. In their report, 5/14 (36%) patients with loss-of-function mutations in IL10RA or IL10RB that did not undergo HSCT-developed lymphoma involving the spleen, liver, bone, or lymph nodes, at the age of 5 to 6 years. Tumor cell analyses showed characteristics of EBV-negative diffuse large B-cell lymphomas containing monoclonal germinal center B cells (7). Two additional cases of EBV-positive B-cell lymphomas in IL-10R–deficient patients have been reported elsewhere (5). The precise mechanism of how loss of IL-10R signaling leads to development of B-cell lymphoma is unclear yet might be related to impaired immune surveillance. IL-10 has been shown to be a key factor for effective tumor immune surveillance by infiltrating CD8+ T cells. IL-10R is highly expressed on CD8+ T cells and, in response to IL-10, leads to increased interferon-γ and granzyme secretion and enhanced antitumor activity (8). Granzyme B expression was shown to be reduced in lymphomas isolated from IL-10R–deficient patients (7). Further support of a role for IL-10R signaling in B-cell lymphoma development is the finding that patients with dominant negative mutations in STAT3, a signaling molecule downstream of IL-10R, can develop large B-cell lymphomas (9). Finally, although it has been postulated that tumorigenesis in patients with IBD may result from thiopurine and/or anti-tumor necrosis factor antibody exposure (10–12), such contribution among IL-10R–deficient subjects has been described as remote because tumors have developed in patients not exposed to immune suppression (7). In conclusion, this case highlights the critical importance of pursuing a diagnosis of IL-10R deficiency in any patient presenting as an infant with severe colitis in association with perianal disease. A missed diagnosis can obviously delay appropriate curative treatment for the intestinal inflammation but also places the patient at great risk of developing large B-cell lymphoma. This case also emphasizes that IL-10R deficiency can present in children from unrelated parents and the diagnosis can remain elusive even in adolescence. Clinicians should be aware of this complication and diagnosis and pursue HSCT early in disease course. Autologous HSCT as a consolidation therapy for patients with chemotherapy-refractory B-cell lymphoma should only be offered in patients with concomitant IBD after IL-10R deficiency has been excluded. If HSCT is not feasible, surveillance steps should be implemented at a young age for early detection of such tumors. Gene replacement or gene therapy approaches, as this field evolves, may be warranted for such patients." @default.
• W2321864672 created "2016-06-24" @default.
• W2321864672 creator A5009137428 @default.
• W2321864672 creator A5019642800 @default.
• W2321864672 creator A5035802660 @default.
• W2321864672 creator A5037348152 @default.
• W2321864672 creator A5052060864 @default.
• W2321864672 creator A5066380716 @default.
• W2321864672 creator A5067320925 @default.
• W2321864672 creator A5089990754 @default.
• W2321864672 date "2016-07-01" @default.
• W2321864672 modified "2023-10-17" @default.
• W2321864672 title "Large B-Cell Lymphoma in an Adolescent Patient With Interleukin-10 Receptor Deficiency and History of Infantile Inflammatory Bowel Disease" @default.
• W2321864672 cites W1995197668 @default.
• W2321864672 cites W1998720681 @default.
• W2321864672 cites W2003821261 @default.
• W2321864672 cites W2008687669 @default.
• W2321864672 cites W2032368145 @default.
• W2321864672 cites W2043897018 @default.
• W2321864672 cites W2058820485 @default.
• W2321864672 cites W2084274092 @default.
• W2321864672 cites W2100942700 @default.
• W2321864672 cites W2116432220 @default.
• W2321864672 cites W2145382951 @default.
• W2321864672 cites W2424946527 @default.
• W2321864672 doi "https://doi.org/10.1097/mpg.0000000000000532" @default.
• W2321864672 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4605893" @default.
• W2321864672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27336593" @default.
• W2321864672 hasPublicationYear "2016" @default.
• W2321864672 type Work @default.
• W2321864672 sameAs 2321864672 @default.
• W2321864672 citedByCount "29" @default.
• W2321864672 countsByYear W23218646722016 @default.
• W2321864672 countsByYear W23218646722017 @default.
• W2321864672 countsByYear W23218646722018 @default.
• W2321864672 countsByYear W23218646722019 @default.
• W2321864672 countsByYear W23218646722020 @default.
• W2321864672 countsByYear W23218646722021 @default.
• W2321864672 countsByYear W23218646722022 @default.
• W2321864672 countsByYear W23218646722023 @default.
• W2321864672 crossrefType "journal-article" @default.
• W2321864672 hasAuthorship W2321864672A5009137428 @default.
• W2321864672 hasAuthorship W2321864672A5019642800 @default.
• W2321864672 hasAuthorship W2321864672A5035802660 @default.
• W2321864672 hasAuthorship W2321864672A5037348152 @default.
• W2321864672 hasAuthorship W2321864672A5052060864 @default.
• W2321864672 hasAuthorship W2321864672A5066380716 @default.
• W2321864672 hasAuthorship W2321864672A5067320925 @default.
• W2321864672 hasAuthorship W2321864672A5089990754 @default.
• W2321864672 hasBestOaLocation W23218646722 @default.
• W2321864672 hasConcept C126322002 @default.
• W2321864672 hasConcept C203014093 @default.
• W2321864672 hasConcept C2778260677 @default.
• W2321864672 hasConcept C2779134260 @default.
• W2321864672 hasConcept C2779338263 @default.
• W2321864672 hasConcept C71924100 @default.
• W2321864672 hasConceptScore W2321864672C126322002 @default.
• W2321864672 hasConceptScore W2321864672C203014093 @default.
• W2321864672 hasConceptScore W2321864672C2778260677 @default.
• W2321864672 hasConceptScore W2321864672C2779134260 @default.
• W2321864672 hasConceptScore W2321864672C2779338263 @default.
• W2321864672 hasConceptScore W2321864672C71924100 @default.
• W2321864672 hasIssue "1" @default.
• W2321864672 hasLocation W23218646721 @default.
• W2321864672 hasLocation W23218646722 @default.
• W2321864672 hasLocation W23218646723 @default.
• W2321864672 hasLocation W23218646724 @default.
• W2321864672 hasOpenAccess W2321864672 @default.
• W2321864672 hasPrimaryLocation W23218646721 @default.
• W2321864672 hasRelatedWork W1493334061 @default.
• W2321864672 hasRelatedWork W1966504330 @default.
• W2321864672 hasRelatedWork W1974041167 @default.
• W2321864672 hasRelatedWork W1979139803 @default.
• W2321864672 hasRelatedWork W2030889776 @default.
• W2321864672 hasRelatedWork W2037631372 @default.
• W2321864672 hasRelatedWork W2070567609 @default.
• W2321864672 hasRelatedWork W2073527559 @default.
• W2321864672 hasRelatedWork W2159000141 @default.
• W2321864672 hasRelatedWork W4207046311 @default.
• W2321864672 hasVolume "63" @default.
• W2321864672 isParatext "false" @default.
• W2321864672 isRetracted "false" @default.
• W2321864672 magId "2321864672" @default.
• W2321864672 workType "article" @default.